CR20210545A - Formas sólidas de un inhibidor de glyt1 - Google Patents

Formas sólidas de un inhibidor de glyt1

Info

Publication number
CR20210545A
CR20210545A CR20210545A CR20210545A CR20210545A CR 20210545 A CR20210545 A CR 20210545A CR 20210545 A CR20210545 A CR 20210545A CR 20210545 A CR20210545 A CR 20210545A CR 20210545 A CR20210545 A CR 20210545A
Authority
CR
Costa Rica
Prior art keywords
solid forms
inhibitor
glyt1 inhibitor
glyt1
glycine transporter
Prior art date
Application number
CR20210545A
Other languages
English (en)
Inventor
Joe Ju Gao
Peter Sieger
Bing-Shiou Yang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20210545A publication Critical patent/CR20210545A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan formas sólidas de un inhibidor del transportador de glicina-1 (GlyT1). La invención también se refiere a métodos para fabricar estas formas sólidas, composiciones farmacéuticas que comprenden estas formas sólidas y su uso para afecciones médicas que responden al tratamiento con un inhibidor del transportador de glicina-1.
CR20210545A 2019-05-01 2020-04-30 Formas sólidas de un inhibidor de glyt1 CR20210545A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841401P 2019-05-01 2019-05-01
PCT/US2020/030580 WO2020223419A1 (en) 2019-05-01 2020-04-30 Solid forms of a glyt1 inhibitor

Publications (1)

Publication Number Publication Date
CR20210545A true CR20210545A (es) 2021-12-23

Family

ID=70740812

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210545A CR20210545A (es) 2019-05-01 2020-04-30 Formas sólidas de un inhibidor de glyt1

Country Status (23)

Country Link
US (2) US11447474B2 (es)
EP (1) EP3962911A1 (es)
JP (1) JP7513349B2 (es)
KR (1) KR20220004174A (es)
CN (1) CN113784966A (es)
AR (1) AR118839A1 (es)
AU (1) AU2020266566A1 (es)
BR (1) BR112021020883A2 (es)
CA (1) CA3138288A1 (es)
CL (1) CL2021002837A1 (es)
CO (1) CO2021014260A2 (es)
CR (1) CR20210545A (es)
DO (1) DOP2021000224A (es)
EA (1) EA202192925A1 (es)
EC (1) ECSP21082195A (es)
IL (1) IL287630A (es)
JO (1) JOP20210295A1 (es)
MA (1) MA55801A (es)
MX (1) MX2021013341A (es)
PE (1) PE20212263A1 (es)
SG (1) SG11202111972YA (es)
TW (1) TW202106680A (es)
WO (1) WO2020223419A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
CN116212025A (zh) 2020-01-09 2023-06-06 迪斯克医药公司 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
AU2021324376A1 (en) * 2020-08-13 2023-02-02 Boehringer Ingelheim International Gmbh Treatment of cognitive impairement associated with schizophrenia
CA3195702A1 (en) 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Process of reworking

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
AP2006003592A0 (en) * 2003-10-14 2006-04-30 Pfizer Prod Inc Bicyclic [3.1.0] derivatives as glycine transporter inhibitors.
EP2373651A1 (en) * 2008-12-04 2011-10-12 Sanofi Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
KR20110117087A (ko) * 2008-12-29 2011-10-26 벤더르빌트 유니버시티 3.1.0 비시클릭 ｇｌｙｔ1 억제제 및 그것을 제조 및 사용하는 방법
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
JP7177042B2 (ja) * 2017-04-27 2022-11-22 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
WO2020223419A1 (en) 2020-11-05
MA55801A (fr) 2022-03-09
PE20212263A1 (es) 2021-11-29
AU2020266566A1 (en) 2021-11-11
TW202106680A (zh) 2021-02-16
AR118839A1 (es) 2021-11-03
JP2022530630A (ja) 2022-06-30
US20200347041A1 (en) 2020-11-05
ECSP21082195A (es) 2021-12-30
CA3138288A1 (en) 2020-11-05
IL287630A (en) 2021-12-01
US20220332710A1 (en) 2022-10-20
JOP20210295A1 (ar) 2023-01-30
SG11202111972YA (en) 2021-11-29
US11447474B2 (en) 2022-09-20
CN113784966A (zh) 2021-12-10
KR20220004174A (ko) 2022-01-11
JP7513349B2 (ja) 2024-07-09
DOP2021000224A (es) 2021-12-15
BR112021020883A2 (pt) 2022-04-19
EP3962911A1 (en) 2022-03-09
CL2021002837A1 (es) 2022-07-29
CO2021014260A2 (es) 2021-10-29
MX2021013341A (es) 2021-11-17
EA202192925A1 (ru) 2022-03-23

Similar Documents

Publication Publication Date Title
MX2021013341A (es) Formas solidas de un inhibidor de glyt1.
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
MX2021009285A (es) Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12018502465A1 (en) Mic-1 compounds and use thereof
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
PH12019550241A1 (en) Mic-1 compounds and uses thereof
GEP20217318B (en) Pyrazole magl inhibitors
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX370065B (es) Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
PH12020551618A1 (en) Erenumab compositions and uses thereof
MX2021007460A (es) Peptidos para el tratamiento y prevencion de diabetes y trastornos asociados.
MX2022000742A (es) Metodo para disminuir los efectos adversos del interferon.
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
AU2017247612A9 (en) Hafnia alvei based pharmaceutical and food compositions for inducing satiation and prolonging satiety
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
PH12017501918A1 (en) Multi-peptide composition
EA202090432A1 (ru) Новые соединения, активирующие путь nrf2